SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending due to record October delivery numbers, marking a significant year-over-year increase that has the community buzzing with excitement. Investors are optimistic about NIO's growing ecosystem and potential for further expansion, particularly with its innovative battery-swapping technology. Community members are closely watching for continued growth and a potential turning point towards profitability.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid speculation about a potential short squeeze and renewed interest in privacy coins. Some community members are drawing comparisons to Bitcoin's early days, while others highlight its limited supply and upcoming halving event. The conversation includes discussion of potential price targets and whether ZEC can outperform other cryptocurrencies.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FCEL is trending amid discussions about its potential role in powering AI data centers, particularly with its natural gas-fueled fuel cell technology. The community is analyzing the ExxonMobil conference call and its implications for FCEL's carbon capture technology, while comparing it to sector peers like Bloom Energy. High trading volume and options activity further fuel the stock's increased attention.

Bounce Token

Bounce Token is trending as traders discuss its potential for significant gains, fueled by its relatively low supply and active development. Community members are pointing to its history of massive pumps, with some anticipating a run to previous highs. The conversation includes speculation on potential price targets and comparison to other low-cap coins.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members highlight its strong ties to the Bitcoin network and its fair launch distribution. Discussion points include its potential for mainstream adoption and comparisons to other memecoins. The community emphasizes its organic growth and increasing recognition within the crypto space.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter (JUP) is trending as community members express bullish sentiment and analyze charts for potential double bottoms. There's also significant discussion around the meme coin $UPDOG, which is listed on Jupiter, with users highlighting its community and potential for becoming a millionaire. Additionally, Jupiter Lend and its features like high LTVs are being discussed.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

MPW is trending as investors weigh mixed Q3 results, including year-over-year revenue growth offset by higher interest expenses and a miss on NFFO per share estimates. The community is actively debating the stock's profitability, potential for a short squeeze given high short interest, and the impact of ongoing restructuring efforts and a recently announced share buyback program. Bullish investors point to equity value exceeding share price and potential for positive EPS, while bears express concerns about rising interest expenses and struggling tenants.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending amid analyst upgrades and anticipation for upcoming earnings, with the community eyeing potential AI-related announcements. Bullish sentiment seems to be building as the stock approaches 52-week highs, while some traders debate the company's valuation. Chatter surrounds a possible acquisition of GitLab which could have impacts in the software space.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending due to concerns around declining deliveries and increased competition in the Chinese EV market, highlighted by a recent drop in stock price and lowered Q3 guidance. Community discussions revolve around the impact of these factors on the company's future profitability and market share, especially compared to competitors like XPeng and NIO. Investors are also weighing potential catalysts, including the upcoming launch of the i6 model and long-term growth prospects.

Zscaler, Inc. engages in the provision of a cloud-based internet security platform. It offers Zero Trust Exchange, Zscaler Client Connector, Zscaler Internet Access, Zscaler Private Access, Zscaler B2B, Zscaler Cloud Protection, and Zscaler Digital Experience. The company was founded by Jagtar Singh Chaudhry and K. Kailash in September 2007 and is headquartered in San Jose, CA.

Zscaler Inc

ZS is trending amid bullish sentiment fueled by a potential breakout, strong technical patterns like a cup and handle, and analyst upgrades. The community is discussing long-term growth potential in the cybersecurity sector, particularly with AI-driven security solutions, and is closely watching for a move past key resistance levels. Some traders express concerns about holding through upcoming earnings, while others point to zero-trust architecture as a catalyst for sustained growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts.Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ with a price target of $7, down from $18. Meanwhile, William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to ‘Market Perform’ from ‘Outperform’ without a price target. Wells Fargo kept its ‘Equal Weight’ rating on the shares but slashed the price target to $5 from $7.Kezar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-announces-regulatory-update-zetomipzomib">announced</a> on Thursday that it has initiated a process to explore strategic alternatives focused on maximizing shareholder value after being unable to align with the U.S. Food and Drug Administration on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis (AIH). Autoimmune hepatitis is a rare, chronic disease that predominantly affects women and, if left untreated, can lead to cirrhosis, liver failure, and hepatocellular carcinoma.However, the FDA Division of Hepatology and Nutrition cancelled a Type C meeting that was previously scheduled with Kezar in the fourth quarter to discuss a proposed study in AIH, the company said.Earlier this year, Kezar reported positive safety and efficacy data from a clinical trial in patients with refractory or relapsed AIH. However, the regulator requested that Kezar conduct a stand-alone study to define the pharmacokinetics of Zetomipzomib in subjects with significant hepatic impairment before the initiation of another clinical trial in AIH.This study would delay future trials of Zetomipzomib in AIH by approximately two years, the company said, while adding that the requirements put forth by the FDA would also hinder patient enrollment and participation.“While we remain excited about the potential of Zetomipzomib to be the first approved agent in AIH, we lack the resources to extend the development timeline,” CEO Chris Kirk said.The company also said it would be implementing a restructuring plan, including layoffs and other cash conservation measures, as part of the strategic alternative evaluation.William Blair said on Friday that it is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.Wells, however, thinks there could be upside if they return cash to shareholders or in a reverse merger scenario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZR">KZR stock</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_12_46_33_PM_png_393ca210c9.webp" alt="KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that $6.50 to $7 would be a good range for the stock.<stembedurl>https://stocktwits.com/StockBoyAri/message/632736011</stembedurl>Another user expressed doubts over the rally.<stembedurl>https://stocktwits.com/CMCanalyst/message/632743196</stembedurl>KZR stock is down by 9% this year and by about 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A">Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Equity

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.


Fossil Group (FOSL) shares were down nearly 39% in premarket trading on Thursday morning after the company said on Thursday that it has further extended the&nbsp;expiration of the exchange offer concerning its 7.00% Senior Notes due 2026.The company also noted that it has extended the consent solicitation and its concurrent rights offering from October 15 to October 22.Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.Retail sentiment on Fossil Group jumped to ‘extremely bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Wednesday, Fossil Group’s shares had closed up 41.5% at a two-and-a-half-year high of $3.75 following the news of the IPO of its Indian unit. According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/fossil-india-is-said-to-weigh-ipo-that-could-raise-400-million">Bloomberg News report</a>, Fossil India was in talks to raise $300 million to $400 million by selling as much as a 25% stake.The report noted that the talks were ongoing and that the size of the IPO or the possible timing of the offering could change.&nbsp;In early 2025, as part of a plan to save costs, the company planned to shut down around 50 retail locations and shift certain international markets to a distributor model. The firm is home to several premium brands such as Fossil Watches and Michele.&nbsp;<a href="https://stocktwits.com/symbol/VERI">Shares of Fossil Group</a> have jumped 125% this year and gained nearly 213% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>

Sign of Fossil Group outside a store in Orlando, Florida.

FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026

Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.

Shares of TrueCar (TRUE) rallied 60% on Wednesday morning after the company said that it has entered into a definitive agreement under which Fair Holdings, Inc., an entity led by TrueCar founder Scott Painter, will acquire the company in an all-cash, go-private transaction at $2.55 per share.This represents a premium of about 72% from the stock’s closing price on Tuesday and amounts to an equity value of approximately $227 million based on current basic shares outstanding.TrueCar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/truecar-to-be-acquired-by-founder-led-strategic-and-financial-investor-group-in-all-cash-go-private-transaction-302584766.html">said</a> that Fair Holdings is negotiating with various financial and strategic investors to syndicate the financing of the deal with equity investments.TrueCar Chair Barbara Carbone said that the board unanimously approved the transaction after a thorough and careful evaluation. “...we are confident it is in the best interest of TrueCar stockholders and other stakeholders,” they added.Upon completion of the deal, Scott Painter will be the CEO of the company again, it said. The transaction is expected to close in the fourth quarter of 2025 or early 2026, subject to the receipt of certain approvals. Once the deal is completed, TrueCar will no longer trade on the bourse.However, if Fair Holdings is unable to complete the transaction, it has agreed to pay a reverse termination fee to TrueCar, the company said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRUE">TRUE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_1_43_05_PM_png_7f46c96902.webp" alt="TRUE's Sentiment Meter and Message Volume as of 1:43 p.m. ET on Oct. 15, 2025 | Source: Stocktwits" width="586" height="63"><figcaption>TRUE's Sentiment Meter and Message Volume as of 1:43 p.m. ET on Oct. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits applauded the buyout as a “good deal.”<stembedurl>https://stocktwits.com/mickymatthews/message/632395006</stembedurl>Another, however, opined that the price is low.<stembedurl>https://stocktwits.com/mickymatthews/message/632389499</stembedurl>TRUE stock is down by 36% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rigetti-computing-stock-slides-8-after-hitting-record-highs-on-tuesday/ch6F2raR3VG">Rigetti Computing Stock Slides 8% After Hitting Record Highs On Tuesday — Traders Warn Of More Downside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Employees of TrueCar celebrate while ringing the opening bell for the Nasdaq Exchange in Times Square on May 16, 2014 in New York City. TrueCar was having it's initial public offering (IPO) on the Nasdaq exchange. (Photo by Andrew Burton/Getty Images)

TrueCar Shares Soar Following $227M Go-Private Deal

The per share purchase price represents an equity value of $227 million and a premium of about 72% from the stock’s closing price on Tuesday. 

Cellectar Biosciences (CLRB) stock tumbled over 17% on Tuesday after the company announced an agreement with several institutional investors to exercise certain existing warrants for gross proceeds of approximately $5.8 million.Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/377/cellectar-biosciences-inc-enters-into-agreements-to-raise">stated</a> that a total of 1.05 million existing warrants were exercised. The company now intends to use the net proceeds for working capital and general corporate purposes in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.The capital raise comes on the heels of Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/376/cellectar-biosciences-announces-european-medicines-agency">announcing</a> that it intends to submit a conditional marketing authorization application to the European Medicines Agency for Iopofosine I 131 as a treatment for refractory Waldenstrom macroglobulinemia in early 2026, following advice from the agency’s Scientific Advice Working Party (SAWP).The company stated that it anticipates European Approval by 2027 and commercial availability of the therapy in the 30 countries represented by the EMA in the same year.“We believe this regulatory success is substantial as it further supports Cellectar’s plans to pursue worldwide approval, including a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) under an accelerated approval pathway,” CEO James Caruso said on Monday, while noting that an NDA submission is contingent upon the company obtaining additional funding to initiate a confirmatory trial.Oppenheimer, which has a ‘Perform rating’ on <a href="https://stocktwits.com/symbol/CLRB">CLRB shares</a>, subsequently noted that the news is a substantial positive catalyst that should bolster the company’s efforts to partner the Iopofosine I 131 program.On Stocktwits, retail sentiment around CLRB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1372/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_11_30_27_AM_png_09a789f2e6.webp" alt="CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1372" height="132"><figcaption>CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the decline in the stock price.<stembedurl>https://stocktwits.com/EvenBetter99/message/631308393</stembedurl>Another user expressed hopes about an impending rally in the shares.<stembedurl>https://stocktwits.com/Slab6/message/631300689</stembedurl>CLRB stock is down 43% this year and approximately 92% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

DFAS
Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DFAS News

DFASDimensional ETF Trust - Dimensional U.S. Small Cap ETF